Sponsored by Academy for Continued Healthcare Learning
Supported by an educational grant from Novartis Pharmaceuticals Corporation
This case-based activity with a patient video illustrates a typical heart failure (HF) case of HF with reduced ejection fraction (HFrEF). Our faculty will discuss guideline recommendations, available clinical trial data, and dosing of optimal, targeted medical therapies for HFrEF.
This activity is intended for interventional cardiologists, cardiologists, primary care physicians, nurses and others with an interest in the care of heart failure.
Upon proper completion of this activity, participants should be better able to:
Discuss strategies to optimize medical therapy in patients with heart failure
Interpret data from recent clinical trials and post-marketing studies with sacubitril/valsartan and ivabradine
Identify diverse HF patients who may benefit from the use of newer medical therapies
Employ multidisciplinary approaches to improve collaboration, transitions of care, and patient outcomes
Conflict of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
Ileana L. Piña, MD, MPH, FAHA, FACC Professor of Medicine, Wayne State University Clinical Prof of Medicine, Central Michigan University Director of CVD Research and Academic Affairs Regional and National Director of Heart Failure Detroit Medical Center, Cardiovascular Institute Detroit, MI
Dr. Piña discloses the following: Advisory Board: Relypsa, Inc.
Tariq Ahmad, MD, MPH, FACC Assistant Professor of Medicine (Cardiology) Advanced Heart Failure and Transplant Cardiologist Investigator, Center for Outcomes Research and Evaluation Yale University School of Medicine Yale New Haven Health System New Haven, CT
Dr. Ahmad discloses the following: Consulting Agreements: Amgen Inc., Cytokinetics, Inc
Navin K. Kapur, MD, FAHA, FACC, FSCAI Associate Professor, Dept of Medicine/Division of Cardiology Executive Director, The CardioVascular Center for Research and Innovation (CVCRI) Director, Acute Circulatory Support Program Director, Interventional Research Laboratories Investigator, Molecular Cardiology Research Institute Tufts Medical Center Boston, MA
Dr. Kapur discloses the following: Grants/Research Support: Abiomed, Abbott, Boston Scientific, Maquet , MD Start, Medtronic Consultant/Advisory Board: Abiomed, Abbott, Boston Scientific, Maquet , MD Start, Medtronic Honorarium/Speakers Bureau: Abiomed, Abbott, Boston Scientific, Maquet , MD Start, Medtronic
Accredited Provider Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Medical therapies and devices under investigation for HF.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available and emailed, please be sure to check spam/junk mailbox. There is no fee to participate in the activity or for the generation of the certificate. Your certificate will be saved on the ACHL website and will not be available in your myCME CME History. If you cannot locate your certificate, please contact Melissa Stradal at firstname.lastname@example.org.